Dr. Andrew Clark: Senior Independent Non-executive Director
Dr. Clark was appointed to the Board of the Company in September 2007. He received his PhD in Neuroscience from St. Andrew’s University and was a post-doctoral research fellow in pharmacology at the University of Oxford. He worked in London as a biotech analyst at Baring Securities. In 1995, he co-founded Reabourne Ltd., an investment management business which focused on small capitalisation technology and biotechnology companies, where he acted as portfolio manager. He left Reabourne in 2003, following the sale of the business, and currently works as a consultant in the biotechnology field. He has held a number of non‑executive directorships of life science and investment companies.
John Garcia: Chairman, Independent Non-executive Director
Mr. Garcia was appointed to the Board of the Company in September 2007. With a 25-year career in the health products industry, he has been instrumental in the development and growth of several medical products and services companies. He served for more than ten years as president of Sulzermedica’s US$300m pacemaker business before it was acquired by Guidant in 1998. He also held sales and marketing management positions with FHP (a California HMO), Bio Science (a national reference lab) and Pharmaseal (a division of American Hospital Supply Corporation).
Eric Swenden: Non-executive Director
Mr. Swenden was appointed to the Board of the Company in 2003. He has had a long and successful career in finance and company management, having held positions on the boards of a broad array of public and private companies, including several drug companies, Vandemoortele Food Group and General Bank (Belgium’s largest bank before its merger with Fortis).
Responsibilities of the Audit Committee
The Audit Committee comprises Dr. Andrew Clark (Chairman), John Garcia and Eric Swenden. The Audit Committee is responsible for assisting the Board in overseeing the integrity of the Company’s financial reports, the Company’s compliance with legal and regulatory requirements, the qualifications, independence and performance of the Company’s independent auditors and the effectiveness of the Company’s internal control systems.